The ELVIS study: Medium and long-term Efficacy of LVIS EVO stent-assisted coil embolisation for unruptured saccular intracranial aneurysms-A tertiary single-centre experience.
Krishna Pranathi Settipalli, Sophie Dunkerton, John Hilton, Grace Aw, Gregory Lock, Kenneth Mitchell, Alan Coulthard
{"title":"The ELVIS study: Medium and long-term Efficacy of LVIS EVO stent-assisted coil embolisation for unruptured saccular intracranial aneurysms-A tertiary single-centre experience.","authors":"Krishna Pranathi Settipalli, Sophie Dunkerton, John Hilton, Grace Aw, Gregory Lock, Kenneth Mitchell, Alan Coulthard","doi":"10.1111/1754-9485.13820","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The LVIS EVO (MicroVention<sup>®</sup>) is a braided stent designed to assist coil embolisation of intracranial aneurysms. It offers several structural innovations over previous and currently available braided, and laser-cut, stents that are theorised to improve procedural success. This retrospective audit aims to determine the success and complication rates of LVIS EVO-assisted coil embolisation in unruptured saccular aneurysms at a tertiary neurovascular referral centre in Queensland, Australia.</p><p><strong>Methods: </strong>The medical records of all patients who underwent elective LVIS EVO-assisted coil embolisation at our institution between 2020 and 2024 were reviewed. Clinical and radiologic outcomes, including occlusion rate, occlusion grade (modified Raymond Roy classification-MRRC), complications, recurrence rate, and change in modified Rankin scale (mRS) were recorded, alongside aneurysm characteristics and technical procedural details.</p><p><strong>Results: </strong>Of 29 cases, 2 were excluded due to complex aneurysms requiring off-label LVIS EVO use. Twenty-seven (27) saccular aneurysms in 26 patients (18 female; 8 male) were included. Most (22/27) involved the anterior cerebral artery (ACA), primarily the anterior communicating artery (18/27). Complete occlusion was seen in 55.6% (15/27) of cases immediately post-procedure, in 85.2% (23/27) at 3 months, and in 84.2% (16/19) at a median of 12-months post-procedure. A recurrence was seen in 7.4% (2/27) of patients. No procedural or long-term complications, and no significant changes in 90-day mRS, were noted.</p><p><strong>Conclusion: </strong>Our results show 100% technical success reflecting existing literature and contribute further by providing data on medium to long-term success rates with LVIS EVO-assisted coil embolisation for unruptured saccular aneurysms.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Imaging and Radiation Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1754-9485.13820","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: The LVIS EVO (MicroVention®) is a braided stent designed to assist coil embolisation of intracranial aneurysms. It offers several structural innovations over previous and currently available braided, and laser-cut, stents that are theorised to improve procedural success. This retrospective audit aims to determine the success and complication rates of LVIS EVO-assisted coil embolisation in unruptured saccular aneurysms at a tertiary neurovascular referral centre in Queensland, Australia.
Methods: The medical records of all patients who underwent elective LVIS EVO-assisted coil embolisation at our institution between 2020 and 2024 were reviewed. Clinical and radiologic outcomes, including occlusion rate, occlusion grade (modified Raymond Roy classification-MRRC), complications, recurrence rate, and change in modified Rankin scale (mRS) were recorded, alongside aneurysm characteristics and technical procedural details.
Results: Of 29 cases, 2 were excluded due to complex aneurysms requiring off-label LVIS EVO use. Twenty-seven (27) saccular aneurysms in 26 patients (18 female; 8 male) were included. Most (22/27) involved the anterior cerebral artery (ACA), primarily the anterior communicating artery (18/27). Complete occlusion was seen in 55.6% (15/27) of cases immediately post-procedure, in 85.2% (23/27) at 3 months, and in 84.2% (16/19) at a median of 12-months post-procedure. A recurrence was seen in 7.4% (2/27) of patients. No procedural or long-term complications, and no significant changes in 90-day mRS, were noted.
Conclusion: Our results show 100% technical success reflecting existing literature and contribute further by providing data on medium to long-term success rates with LVIS EVO-assisted coil embolisation for unruptured saccular aneurysms.
简介：LVIS EVO (MicroVention®) 是一种编织支架，设计用于辅助颅内动脉瘤的线圈栓塞。与以前和目前可用的编织支架和激光切割支架相比，它在结构上进行了多项创新，理论上可提高手术成功率。这项回顾性审计旨在确定澳大利亚昆士兰州一家三级神经血管转诊中心在 LVIS EVO 辅助线圈栓塞治疗未破裂囊状动脉瘤的成功率和并发症发生率：方法：回顾了2020年至2024年期间在本院接受选择性LVIS EVO辅助线圈栓塞术的所有患者的病历。记录了临床和放射学结果，包括闭塞率、闭塞等级（改良雷蒙德-罗伊分级-MRRC）、并发症、复发率和改良兰金量表（mRS）的变化，以及动脉瘤特征和手术技术细节：结果：在29个病例中，有2个因复杂动脉瘤需要标签外使用LVIS EVO而被排除在外。共纳入26名患者（18名女性；8名男性）的27个囊状动脉瘤。大多数（22/27）涉及大脑前动脉（ACA），主要是前交通动脉（18/27）。55.6%的病例（15/27）在术后立即完全闭塞，85.2%的病例（23/27）在术后3个月完全闭塞，84.2%的病例（16/19）在术后12个月完全闭塞。7.4%（2/27）的患者复发。没有发现手术或长期并发症，90天的mRS也没有明显变化：我们的研究结果显示技术成功率为100%，反映了现有文献的研究结果，并提供了LVIS EVO辅助线圈栓塞治疗未破裂囊状动脉瘤的中长期成功率数据，为研究做出了进一步贡献。
期刊介绍：
Journal of Medical Imaging and Radiation Oncology (formerly Australasian Radiology) is the official journal of The Royal Australian and New Zealand College of Radiologists, publishing articles of scientific excellence in radiology and radiation oncology. Manuscripts are judged on the basis of their contribution of original data and ideas or interpretation. All articles are peer reviewed.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
